2-Schagdarsurengin U O, Gimm H, Dralle C, Hoang-Vu, Dammann R. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 2006;16: 633-42.
3-Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, ‘et al’. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 2005; 90: 2512-21.
4-Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110: 38-46.
5-Shibru D J, Hwang E, Khanafshar QY, Duh OH, Clark, Kebebew E. Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms?. Cancer 2008; 113: 930-5.
6-Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery 2005; 138: 1102-9.
7-Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA,’et a’l. Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab 2005; 90: 4011-8.
8-Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, ‘et al’. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006; 65: 660-6.
9-Rowe LRM, Bentz BGM, Bentz JSM. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 2006; 3: 10.
10-Asa SL. The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocr Pathol 2005; 16: 295-309.
11-Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, ‘et al’. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 2004; 113: 1234-42.
12-Nikiforova M, Durso MB, Kelly LM, Nikiforov YE. Testing for 740 Mutations in Thyroid Samples Using Targeted Next Generation Sequencing Approach. In: 82nd Annual Meeting of the American Thyroid Association; 2012 Sep 19-23 ; Quebec, Canada; 2012. p. A-79.
13-Song Q, Wang D, Lou Y, Li C, Fang C, He X, ‘et al’. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol 2011; 6: 126.
14-Xing M. Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 2008; 41: 1135-46.
15-Fryknas M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, ‘et al’. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol 2006; 27: 211-20.
16-Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, Nagele RG, ‘et al’. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci 2008; 99: 1326-33.
17-Sakashita K, Mimori K, Tanaka F, Kamohara Y, Inoue H, Sawada T, ‘et al’. Clinical significance of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol 2008; 15: 2293-300.
18-Mohammadi-Asl J, Dinarvand GhA, Golchin N, Saki N, Ranjberi N, Rashidi I. The Diagnostic Value of Gene Expression of FHL1 in the Differential Diagnosis of Papillary Thyroid Carcinoma and Benign Tumors. J Isfahan Med Sch 2014; 31(266): 1-9.